

REPORT 2021



About IDIBAPS

The Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) is a biomedical research institute of excellence. It combines clinical and basic research to accelerate the translation of knowledge to the benefit of the patients.

Founded in 1996, it is a public consortium formed by the Generalitat de Catalunya, Hospital Clínic de Barcelona, Faculty of Medicine and Health Sciences of the Universitat de Barcelona and, as an associated center, the CSIC's Barcelona Biomedical Research Institute.

The research activities of IDIBAPS are structured into 5 areas. Additionally, 3 transversal groups perform research in "primary care", "nursing" and "pharmacology and clinical trials".

About FUNDACIÓ CLÍNIC


The Fundació Clínic per a la Recerca Biomèdica

(FCRB) is a non-profit foundation, covered by the law of patronage, that provides researchers from IDIBAPS and Hospital Clínic of Barcelona, with overall administrative and management support.


Founded in 1989, it also works to attract resources for research and, through the Aula Clínic and Eixample Clínic platforms, it promotes and disseminates continuous training in health sciences.



Research areas



Original articles




Funding sources (consolidated IDIBAPS + FCRB)

Funding sources

1	Competitive funding	20,918,034€	33.3%
2	Private funding	21,700,472€	34.5%
3	Donations	5,990,516€	9.5%
4	Knowledge dissemination	2,792,348€	4.4%
5	Generalitat de Catalunya	7,003,179€	11.1%
6	Core facilities	1,139,117 €	1.8%
7	Rental income	783,026€	1.2%
8	Intercompany services	420,809€	0.7%
9	Financial income	11,752€	0.1%
10	Capital grant	2,046,683€	3.3%

TOTAL 62,805,938 €



1.2%

5.8%

598,352€

Transversal


Other research 2,977,071 €






Predoctoral researchers (R1) **35%** 173 **65%** 316 24% 489 Postdoctoral researchers (R2A+R2B+R2C) 374 **34%** 128 18% **66%** 246 Researchers (R3A) **47%** 191 **53%** 218 20% 409 Junior group leaders (R3B) 15 1% **53%** 8 **47%** 7 Group leaders (R4) **26%** 24 **74%** 68 92 5% **Technical support personnel** (*administratives* + *technicians* + *nurses*) **18%** 58 **82%** 260 318 16% Associated HCB researchers 8% **57%** 88 **43%** 67 155 Core facilities **25%** 10 **75%** 30 2% 40 Management staff **35%** 47 **65%** 86 7% 133


New competitive projects




Active competitive projects



Core facilities



Innovation and education



Institutional news

February

- Low birth weight triples the risk of suffering severe COVID-19 in patients under 70 years of age.
- Barcelona researchers draw 3D map of the genome of healthy and cancerous lymphocytes.

March

- A study in Nature concludes that immunotherapy is less efficacious in nonviral liver cancer.
- A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer.

April

 In one year, IDIBAPS-Hospital Clínic collects over 40,000 samples from COVID-19 patients for research purposes.

May

• IDIBAPS incorporates the 'Translational genomics of colorectal cancer' research group.

June

- Clínic-IDIBAPS researchers identify a new autoimmune encephalitis.
- A study with over 700,000 patients enables the age of onset of different mental disorders to be established.

September

• The COVID-19 pandemic caused primary care diagnoses of common diseases to fall by up to 50%.

October

- BACE2 inhibition aggravates the metabolic consequences of a high-fat diet in mice.
- Identified a new mechanism that promotes angiogenesis in chronic liver disease.
- IDIBAPS signs the transparency agreement on the use of animals in scientific experimentation in Spain.

November

- Eight researchers at Hospital Clínic-IDIBAPS and Universitat de Barcelona in the ranking of the best in the world.
- More than 50 IDIBAPS Clinic researchers on Stanford University's list of most influential scientists.
- Nearly 250 students take part in the IDIBAPS science workshops for Science Week.

December

 Hospital Clínic-IDIBAPS has developed a CAR-T cell therapy for multiple myeloma that shows an effectiveness of over 70% after one-year follow-up.







Rosselló, 149-153 08036 Barcelona

idibaps.org facebook.com/idibaps @idibaps